Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients.

Critically ill Intensive care Machine learning Piperacillin/tazobactam Population pharmacokinetics Therapeutic drug monitoring Uncertainty quantification

Journal

BMC medical informatics and decision making
ISSN: 1472-6947
Titre abrégé: BMC Med Inform Decis Mak
Pays: England
ID NLM: 101088682

Informations de publication

Date de publication:
25 08 2022
Historique:
received: 16 03 2022
accepted: 10 08 2022
entrez: 25 8 2022
pubmed: 26 8 2022
medline: 30 8 2022
Statut: epublish

Résumé

Beta-lactam antimicrobial concentrations are frequently suboptimal in critically ill patients. Population pharmacokinetic (PopPK) modeling is the golden standard to predict drug concentrations. However, currently available PopPK models often lack predictive accuracy, making them less suited to guide dosing regimen adaptations. Furthermore, many currently developed models for clinical applications often lack uncertainty quantification. We, therefore, aimed to develop machine learning (ML) models for the prediction of piperacillin plasma concentrations while also providing uncertainty quantification with the aim of clinical practice. Blood samples for piperacillin analysis were prospectively collected from critically ill patients receiving continuous infusion of piperacillin/tazobactam. Interpretable ML models for the prediction of piperacillin concentrations were designed using CatBoost and Gaussian processes. Distribution-based Uncertainty Quantification was added to the CatBoost model using a proposed Quantile Ensemble method, useable for any model optimizing a quantile function. These models are subsequently evaluated using the distribution coverage error, a proposed interpretable uncertainty quantification calibration metric. Development and internal evaluation of the ML models were performed on the Ghent University Hospital database (752 piperacillin concentrations from 282 patients). Ensuing, ML models were compared with a published PopPK model on a database from the University Medical Centre of Groningen where a different dosing regimen is used (46 piperacillin concentrations from 15 patients.). The best performing model was the Catboost model with an RMSE and [Formula: see text] of 31.94-0.64 and 33.53-0.60 for internal evaluation with and without previous concentration. Furthermore, the results prove the added value of the proposed Quantile Ensemble model in providing clinically useful individualized uncertainty predictions and show the limits of homoscedastic methods like Gaussian Processes in clinical applications. Our results show that ML models can consistently estimate piperacillin concentrations with acceptable and high predictive accuracy when identical dosing regimens as in the training data are used while providing highly relevant uncertainty predictions. However, generalization capabilities to other dosing schemes are limited. Notwithstanding, incorporating ML models in therapeutic drug monitoring programs seems definitely promising and the current work provides a basis for validating the model in clinical practice.

Sections du résumé

BACKGROUND
Beta-lactam antimicrobial concentrations are frequently suboptimal in critically ill patients. Population pharmacokinetic (PopPK) modeling is the golden standard to predict drug concentrations. However, currently available PopPK models often lack predictive accuracy, making them less suited to guide dosing regimen adaptations. Furthermore, many currently developed models for clinical applications often lack uncertainty quantification. We, therefore, aimed to develop machine learning (ML) models for the prediction of piperacillin plasma concentrations while also providing uncertainty quantification with the aim of clinical practice.
METHODS
Blood samples for piperacillin analysis were prospectively collected from critically ill patients receiving continuous infusion of piperacillin/tazobactam. Interpretable ML models for the prediction of piperacillin concentrations were designed using CatBoost and Gaussian processes. Distribution-based Uncertainty Quantification was added to the CatBoost model using a proposed Quantile Ensemble method, useable for any model optimizing a quantile function. These models are subsequently evaluated using the distribution coverage error, a proposed interpretable uncertainty quantification calibration metric. Development and internal evaluation of the ML models were performed on the Ghent University Hospital database (752 piperacillin concentrations from 282 patients). Ensuing, ML models were compared with a published PopPK model on a database from the University Medical Centre of Groningen where a different dosing regimen is used (46 piperacillin concentrations from 15 patients.).
RESULTS
The best performing model was the Catboost model with an RMSE and [Formula: see text] of 31.94-0.64 and 33.53-0.60 for internal evaluation with and without previous concentration. Furthermore, the results prove the added value of the proposed Quantile Ensemble model in providing clinically useful individualized uncertainty predictions and show the limits of homoscedastic methods like Gaussian Processes in clinical applications.
CONCLUSIONS
Our results show that ML models can consistently estimate piperacillin concentrations with acceptable and high predictive accuracy when identical dosing regimens as in the training data are used while providing highly relevant uncertainty predictions. However, generalization capabilities to other dosing schemes are limited. Notwithstanding, incorporating ML models in therapeutic drug monitoring programs seems definitely promising and the current work provides a basis for validating the model in clinical practice.

Identifiants

pubmed: 36008808
doi: 10.1186/s12911-022-01970-y
pii: 10.1186/s12911-022-01970-y
pmc: PMC9404625
doi:

Substances chimiques

Anti-Bacterial Agents 0
Piperacillin, Tazobactam Drug Combination 157044-21-8
Piperacillin X00B0D5O0E

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

224

Informations de copyright

© 2022. The Author(s).

Références

Lancet Infect Dis. 2014 Jun;14(6):498-509
pubmed: 24768475
Intensive Care Med. 2021 Dec;47(12):1481-1483
pubmed: 34633485
Ther Drug Monit. 2021 Feb 1;43(1):126-130
pubmed: 33278242
J Antimicrob Chemother. 2014 May;69(5):1416-23
pubmed: 24443514
Clin Pharmacokinet. 2021 Feb;60(2):191-203
pubmed: 32720301
Clin Infect Dis. 2012 Sep;55(6):807-15
pubmed: 22700828
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Nephron. 1976;16(1):31-41
pubmed: 1244564
J Antimicrob Chemother. 2015 Sep;70(9):2671-7
pubmed: 26169558
Pharmaceutics. 2022 May 09;14(5):
pubmed: 35631610
Open Forum Infect Dis. 2018 Nov 19;5(12):ofy313
pubmed: 30555852
J Antimicrob Chemother. 2019 Feb 1;74(2):432-441
pubmed: 30376103
Intensive Care Med. 2019 May;45(5):715-718
pubmed: 30637444
Intensive Care Med. 2017 Jul;43(7):1021-1032
pubmed: 28409203
Nat Methods. 2018 Apr;15(4):233-234
pubmed: 30100822
Pharm Res. 1995 Mar;12(3):406-12
pubmed: 7617529
Front Psychiatry. 2021 Nov 18;12:711868
pubmed: 34867511
Int J Antimicrob Agents. 2017 Jul;50(1):68-73
pubmed: 28501674
CPT Pharmacometrics Syst Pharmacol. 2018 Jun;7(6):360-373
pubmed: 29388347
Antimicrob Agents Chemother. 2015 Mar;59(3):1411-7
pubmed: 25512414
Sci Rep. 2017 Feb 08;7:42192
pubmed: 28176850
Int J Antimicrob Agents. 2019 Dec;54(6):741-749
pubmed: 31479741
Am J Respir Crit Care Med. 2016 Sep 15;194(6):681-91
pubmed: 26974879
Crit Care. 2011;15(5):R206
pubmed: 21914174
Front Med (Lausanne). 2022 Mar 08;9:808969
pubmed: 35360734
Lancet. 2018 Dec 23;390(10114):2739
pubmed: 29303711
Clin Microbiol Infect. 2019 Oct;25(10):1286.e1-1286.e7
pubmed: 30872102
Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1017-31
pubmed: 20636224
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
Intensive Care Med. 2018 Feb;44(2):189-196
pubmed: 29288367
Pharmgenomics Pers Med. 2022 Feb 22;15:143-155
pubmed: 35228813
Crit Care Med. 2017 Feb;45(2):331-336
pubmed: 28098629
PLoS One. 2015 Aug 25;10(8):e0135784
pubmed: 26305568
Clin Pharmacokinet. 2019 Jun;58(6):767-780
pubmed: 30656565
Int J Antimicrob Agents. 2015 Oct;46(4):367-75
pubmed: 26271599
Infection. 2019 Dec;47(6):1001-1011
pubmed: 31473974
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:89-94
pubmed: 25531875
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28717035
Clin Pharmacokinet. 2012 Sep 1;51(9):573-90
pubmed: 22799590
J Int Med Res. 2009 Nov-Dec;37(6):1680-91
pubmed: 20146865

Auteurs

Jarne Verhaeghe (J)

IDLab, Department of Information Technology, Ghent University - imec, Ghent, Belgium. jarne.verhaeghe@ugent.be.

Sofie A M Dhaese (SAM)

Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.

Thomas De Corte (T)

Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.

David Vander Mijnsbrugge (D)

IDLab, Department of Information Technology, Ghent University - imec, Ghent, Belgium.

Heleen Aardema (H)

Department of Critical Care, University Medical Center Groningen, Groningen, The Netherlands.

Jan G Zijlstra (JG)

Department of Critical Care, University Medical Center Groningen, Groningen, The Netherlands.

Alain G Verstraete (AG)

Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.

Veronique Stove (V)

Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.

Pieter Colin (P)

Department of Anesthesiology, University Medical Center Groningen, Groningen, The Netherlands.

Femke Ongenae (F)

IDLab, Department of Information Technology, Ghent University - imec, Ghent, Belgium.

Jan J De Waele (JJ)

Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium.

Sofie Van Hoecke (S)

IDLab, Department of Information Technology, Ghent University - imec, Ghent, Belgium. sofie.vanhoecke@ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH